Dr. Kim Chi

Dr. Kim Chi

M.D. University of Ottawa, 1993
Fellow, Royal College of Physicians & Surgeons of Canada (Internal Medicine), 1997
Fellowship, Medical Oncology, BCCA, 1998
Fellowship, CAMO/GlaxoWellcome Research Oncology, BCCA, 1999

Team: 
Clinical and Research Scientists
Positions: 

Senior Research Scientist, Vancouver Prostate Centre
Chief Medical Officer & Vice President, BC Cancer
Medical Oncologist, BC Cancer  – Vancouver
Professor, Department of Medicine, UBC

 

Dr. Chi is a medical oncologist with BC Cancer who, at a relatively early stage in his career, has received national and international recognition for his contributions to prostate cancer research.

Dr. Chi's research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs.  This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance. He has had peer reviewed grant funding for the conduct of early phase clinical trials and associated correlative studies from the Canada Institutes of Health Research (CIHR), Canadian Cancer Society Research Institute, The U.S. Department of Defense, the Prostate Cancer Foundation (USA), Movember and Prostate Cancer Canada.  Nationally and internationally he has led a number of multi-centre Phase I, II and III clinical trials including cooperative group studies and investigator sponsored studies with agents sourced from the US National Cancer Institute's Cancer Therapy Evaluation Program (NCI CTEP) and industry collaborators. He has led the phase I through III development of two novel compounds (OGX-011 and OGX-427), which came from academic preclinical development at the Vancouver Prostate Centre. He has also contributed to clinical trials that established new standard of care for patients with advanced prostate cancer (docetaxel, abiraterone acetate, enzalutamide).

On July 1, 2019, Dr. Chi was appointed Vice President and Chief Medical Officer, BC Cancer. Prior to this, he was the medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre. He was appointed Chair of the Genitourinary Systemic Group at the BC Cancer Agency in 2003. This group is responsible for developing systemic treatment management guidelines for patients with genitourinary cancers in the province of British Columbia (available at www.bccancer.bc.ca) and securing access to new therapies through the province’s health care system.  Under his guidance as medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre (which provides access for patients to the latest in investigational new drugs through phase I, II and III clinical studies), the not-for-profit Clinical Trials Unit almost doubled patient accrual to trials, becoming a self-sustaining growth operation.

Dr. Chi is Professor with the Department of Medicine at the University of British Columbia.  He is also the Co-Chair of the Genitourinary Disease Site for the Canadian Cancer Trials Group (CCTG) and the Canadian Uro-Oncology Group, which is responsible for developing the genitourinary cancer trials undertaken by investigators at a national cooperative group level. In addition, he is an Executive Committee Member and Past-Chair of the Investigational New Drug Site for the CCTG, which is responsible for developing early phase I/II trials across the CCTG disease sites.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 

Employment

Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov